MirImmune
Cambridge · Founded 2015
About MirImmune
MirImmune is a biopharmaceutical company focused on the development of new and improved immunotherapies for cancer. Aiming to achieve long-term survival of cancer patients, MirImmune combine two leading approaches to cancer treatment: immune checkpoint inhibition and cell-based immunotherapies.
Company Facts
- Founded: 2015
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Website: mirimmunebio.com
- Phone: 508-767-3861
Social Profiles
Canonical: https://fsome.com/organization/mirimmune-8394166 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.